Avantra Biosciences Corporation today announced that effective immediately it is changing its name to Courtagen Life Sciences, Inc. The company will continue to use the Avantra name for their proteomics portfolio, which includes the Avantra Biomarker System. The Avantra Biomarker System offers users rapid, easy-to-use, quantitative multiplex protein assays using catalog or custom reagents.
Brian McKernan, CEO of Courtagen Life Sciences explained, "The name change reflects the Company's new strategic focus on developing advanced technologies in both genomic and proteomic areas and our commitment to bring additional needed technologies to the market."